Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV

被引：0
|
作者：
Marathe, Dhananjay [1 ]
Arora, Priyanka [1 ]
Zhang, Haeyoung [1 ]
Hindman, Jason [1 ]
Liu, Hui [1 ]
Girish, Sandhya [1 ]
Davis, Casey [1 ]
Palaparthy, Ramesh [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
26
引用
收藏
页码：19 / 19
页数：1
相关论文
共 38 条
  • [21] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV aged 65 years or older: W24 results of the BICOLDER study - IMEA 057
    Allavena, C.
    Joly, V.
    Assoumou, L.
    Isernia, V.
    Ajana, F.
    Neau, D.
    Descamps, D.
    Charpentier, C.
    Benalycherif, A.
    Metivier, E.
    Peytavin, G.
    Phung, B.
    Landman, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 47 - 47
  • [22] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study
    Mallolas, J.
    Esposito, V.
    Hocqueloux, L.
    Lambert, J. S.
    Levy, I.
    Wyen, C.
    van Welzen, B.
    Ustianowski, A.
    Schreiber, S.
    Thorpe, D.
    Heinzkill, M.
    Marongiu, A.
    Haubrich, R.
    Loemba, H.
    HIV MEDICINE, 2021, 22 : 115 - 116
  • [23] Association between fentanyl use and virologic suppression in an HIV-infected cohort of people who use/inject drugs (PWID): results from a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) switch study
    Conway, B.
    Yi, S.
    Sharma, S.
    Yung, R.
    Truong, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 121 - 122
  • [24] Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): the BICSTaR cohort
    Knechten, H.
    Milinkovic, A.
    Stephan, C. C.
    Brunetta, J.
    Trottier, B.
    Bonnet, F.
    Duvivier, C.
    Welzen, B. V.
    Mack, F.
    Tossonian, H.
    Thorpe, D.
    Cornejo, A. T.
    Marongiu, A.
    Curbelo, R.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [25] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, C.
    Stoehr, A.
    Wong, A.
    De Wet, J.
    Zeggagh, J.
    Hocqueloux, L.
    Welzen, B. V.
    Heinzkill, M.
    Sahali, S.
    Cornejo, A.
    Ramroth, H.
    Haubrich, R.
    Thorpe, D.
    Lambert, J.
    Kim, C.
    HIV MEDICINE, 2021, 22 : 24 - 24
  • [26] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, Christoph
    Stoehr, Albrecht
    Wong, Alexander
    de Wet, Joss
    Zeggagh, Jeremy
    Hocqueloux, Laurent
    van Welzen, Berend
    Heinzkill, Marion
    Sahali, Sabrinel
    Cornejo, Almudena Torres
    Ramroth, Heribert
    Haubrich, Richard
    Thorpe, David
    Kim, Connie
    INFECTION, 2021, 49 (SUPPL 1) : S16 - S16
  • [27] Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study
    Cano-Smith, J.
    Delgado-Hierro, A.
    Valencia, E.
    Ramos, L.
    Busca, C.
    Mican, R.
    Martin-Carbonero, L.
    Montes, M. L.
    De Miguel, R.
    Montejano, R.
    Moreno, V.
    Perez-Sadaba, F.
    Perez-Rambla, C.
    Molina, R.
    Gonzalez-Garcia, J.
    Bernardino, J. I.
    HIV MEDICINE, 2023, 24 : 411 - 412
  • [28] Switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study
    Esser, S.
    Trottier, B.
    Antinori, A.
    Hila, E.
    Antela, A.
    Tigen, E. Tukenmez
    Boffito, M.
    Lambert, J. S.
    van Welzen, B. J.
    Mack, F.
    Schreiber, S.
    Cassidy, T.
    Harrison, R.
    Saifi, T.
    Sabranski, M.
    Vassallo, M.
    HIV MEDICINE, 2023, 24 : 412 - 414
  • [29] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
    Yokomaku, Yoshiyuki
    Teruya, Katsuji
    Watanabe, Dai
    Endo, Tomoyuki
    Minami, Rumi
    Taguchi, Nao
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Shirasaka, Takuma
    Oka, Shinichi
    PLOS ONE, 2025, 20 (01):
  • [30] Bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in antiretroviral treatment-naive (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort
    Sabranski, M.
    Vassallo, M.
    de Wet, J.
    Rieke, A.
    Wong, A.
    Thorpe, D.
    Cassidy, T.
    Marongiu, A.
    Robineau, O.
    HIV MEDICINE, 2023, 24 : 84 - 87
1234